[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334432-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334432-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-phase-ii-study-of-neoadjuvant-pldcyclophosphamide-and-sequential-nab-paclitaxel-plus-dual-her2-blockade-in-her2-positive-breast-cancer-phase-ii-study","A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer - Phase II study","","Neoadjuvant trastuzumab/pertuzumab plus chemotherapy shows promising efficacy in HER2-positive breast cancer, yet additional cardiotoxicity remains. This single-arm Phase II trial (Brecan) evaluated PLD/cyclophosphamide and sequential nab-paclitaxel based on HP (PLD/C/HP-nabP/HP). Eligible stage IIA–IIIC patients received 4 cycles followed by 4 cycles; primary endpoint was pathological complete response. In 96 enrolled patients, pCR reached 80.2% with low high-grade cardiac toxicity and no treatment-related deaths.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-phase-ii-study-of-neoadjuvant-pldcyclophosphamide-and-sequential-nab-paclitaxel-plus-dual-her2-blockade-in-her2-positive-breast-cancer-phase-ii-study/334432/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-phase-ii-study-of-neoadjuvant-pldcyclophosphamide-and-sequential-nab-paclitaxel-plus-dual-her2-blockade-in-her2-positive-breast-cancer-phase-ii-study/334432.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary objective of the Brecan Phase II trial?","Question",{"text":63,"@type":64},"The primary endpoint was the pathological complete response (pCR).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the neoadjuvant treatment regimen administered in the study?",{"text":68,"@type":64},"Patients received 4 cycles of PLD, cyclophosphamide, and HP, followed by 4 cycles of nab-paclitaxel and HP, with definitive surgery planned after 21 days for appropriate patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What cardiac safety outcomes were reported?",{"text":72,"@type":64},"Four patients (4.2%) experienced left ventricular insufficiency with an absolute LVEF decline; no congestive heart failure and no ≥grade 3 cardiac toxicity occurred, and no treatment-related deaths were reported.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334432,1790115216,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer  \nJi-Xin Yang1,‡, Yu-Qing Yang1,‡, Wen-Yu Hu1,‡, Lu Yang1, Jiang Wu1, Xin-Xin Wen1, Jing Yu1, Mei-Ling Huang1, Dong-Dong Xu1, Dan-Chen Tie1, Lei Wang1, Fan-Fan Li2, Nan-Lin Li1,*  \n1Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University, Xi’an 710032, People’s Republic of China  \n2Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, People’s Republic of China  \n*Corresponding author: Nan-Lin Li, Department of Thyroid Breast and Vascular Surgery, Xijing Hospital of Air Force Military Medical University, No. 127, Changle West Road, Xincheng District, Xi’an 710032, Shanxi Province, People’s Republic of China. Tel: +13709113279; E-mail: [nanlin-74@163.com](nanlin-74@163.com)[ ](nanlin-74@163.com)‡Contributed equally as co-first authors.  \nAbstract  \nBackground: Neoadjuvant trastuzumab/pertuzumab (HP) plus chemotherapy for HER2-positive breast cancer (BC) achieved promising efficacy. The additional cardiotoxicity still existed. Brecan study evaluated the efficacy and safety of neoadjuvant pegylated liposomal doxorubicin (PLD)/ cyclophosphamide and sequential nab-paclitaxel based on HP (PLD/C/HP-nabP/HP) .  \nPatients and Methods: Brecan was a single-arm phase II study. Eligible patients with stages IIA-IIIC HER2-positive BC received 4 cycles of PLD, cyclophosphamide, and HP, followed by 4 cycles of nab-paclitaxel and HP. Definitive surgery was scheduled after 21 days for patients completing treatment or experiencing intolerable toxicity. The primary endpoint was the pathological complete response (pCR) .  \nResults: Between January 2020 and December 2021, 96 patients were enrolled. Ninety-five (99 .0%) patients received 8 cycles of neoadjuvant therapy and all underwent surgery with 45 (46 .9%) breast-conserving surgery and 51 (53 . 1%) mastectomy. The pCR was 80.2%(95%CI, 71.2% - 87.0%) . Four (4 .2%) experienced left ventricular insufficiency with an absolute decline in LVEF (43%-49%) . No congestive heart failure and ≥grade 3 cardiac toxicity occurred. The objective response rate was 85.4%(95%CI, 77.0%-91. 1%), including 57 (59 .4%) complete responsesand 25 (26 .0%) partial responses. The disease control rate was 99.0%(95%CI, 94.3%-99 .8%) . For overall safety, ≥grade 3 AEs occurred in 30 (31.3%) and mainly included neutropenia (30 .2%) and asthenia (8 .3%) . No treatment-related deaths occurred. Notably, age of >30 ( P = .01; OR = 5.086; 95%CI, 1.44-17.965) and HER2 IHC 3+ ( P = .02; OR = 4.398; 95%CI, 1.286-15.002) were independent predictors for superior pCR ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier NCT05346107) .  \nConclusion: Brecan study demonstrated the encouraging safety and efficacy of neoadjuvant PLD/C/HP-nabP/HP, suggesting a potential therapeutic option in HER2-positive BC.  \nKey words: breast cancer; HER2 positive; neoadjuvant therapy; pegylated liposomal doxorubicin (PLD); dual HER2 blockade;  \nImplications for Practice  \nThe pathologic complete response was 80.2%(95%C I, 71.2%-87.0%) . Four (4 .2%) experienced left ventricular insufficiency with an absolute decline in LVEF (43%-49%) . No congestive heart failure and ≥grade 3 cardiac toxicity occurred. Age of >30 years (OR = 5.086) and HER2 IHC 3+ (OR = 4.398) were independent predictors for superior pCR. This regimen may provide a new promising treatment option with a relatively higher pCR and lower cardiac toxicity for patients with HER2-positive positive breast cancer. Patients with age of >30 or HER2 IHC 3+ tumors seemed to achieve a higher pCR rate.  \nIntroduction  \nThe overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15%-25% of breast cancer (BC),1 which conferred an aggressive phenotype and poor prognosis.2 However, the application of targeted drugs as the neoadjuvant therapy significantly","cbCaiaFL9UA2xQ5d","https://ap.wps.com/l/cbCaiaFL9UA2xQ5d","pdf",4164345,"English","# Abstract\n## Background\n## Patients and Methods\n## Results\n## Conclusion\n## Implications for Practice\n# Introduction","[{\"question\":\"What was the primary objective of the Brecan Phase II trial?\",\"answer\":\"The primary endpoint was the pathological complete response (pCR).\"},{\"question\":\"How was the neoadjuvant treatment regimen administered in the study?\",\"answer\":\"Patients received 4 cycles of PLD, cyclophosphamide, and HP, followed by 4 cycles of nab-paclitaxel and HP, with definitive surgery planned after 21 days for appropriate patients.\"},{\"question\":\"What cardiac safety outcomes were reported?\",\"answer\":\"Four patients (4.2%) experienced left ventricular insufficiency with an absolute LVEF decline; no congestive heart failure and no ≥grade 3 cardiac toxicity occurred, and no treatment-related deaths were reported.\"}]","A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer - Phase II study | PDF",1790006629,25]